Literature DB >> 9628819

The structures of the mouse and human urocortin genes (Ucn and UCN).

L Zhao1, C J Donaldson, G W Smith, W W Vale.   

Abstract

The mouse and human urocortin genes (Ucn and UCN, respectively) have been isolated, characterized, and found to have very similar structures. Each has two exons, and the entire coding region is located in the second exon, as is the case for the gene of the related peptide, corticotropin-releasing factor. Several putative transcription factor-binding sites were identified in each of the urocortin promoters, including a TATA box, a cyclic AMP response element (CRE), GATA-binding sites, and a C/EBP-binding site as well as a Brn-2-binding site(s). Sequence analyses of the mouse and human genes also revealed the presence of a previously identified gene, Mpv17, in the 5' region upstream of the urocortin gene. Functional studies following transient transfection of urocortin reporter plasmids in PC12 cells revealed that the urocortin promoter is controlled by both positive and negative elements; the CRE is important for basal activity as well as responsiveness to forskolin stimulation. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628819     DOI: 10.1006/geno.1998.5292

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  18 in total

1.  Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems.

Authors:  K H Skelton; C B Nemeroff; D L Knight; M J Owens
Journal:  J Neurosci       Date:  2000-02-01       Impact factor: 6.167

2.  Corticotropin releasing hormone and related peptides can act as bioregulatory factors in human keratinocytes.

Authors:  A T Slominski; B Roloff; B Zbytek; E T Wei; K Fechner; J Curry; J Wortsman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-03       Impact factor: 2.416

Review 3.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

4.  Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH.

Authors:  S C Weninger; A J Dunn; L J Muglia; P Dikkes; K A Miczek; A H Swiergiel; C W Berridge; J A Majzoub
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Glomerular overproduction of oxygen radicals in Mpv17 gene-inactivated mice causes podocyte foot process flattening and proteinuria: A model of steroid-resistant nephrosis sensitive to radical scavenger therapy.

Authors:  C J Binder; H Weiher; M Exner; D Kerjaschki
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 6.  Corticotropin-releasing factor signaling and visceral response to stress.

Authors:  Andreas Stengel; Yvette Taché
Journal:  Exp Biol Med (Maywood)       Date:  2010-10

7.  Urocortin I inhibits the effects of ghrelin and neuropeptide Y on feeding and energy substrate utilization.

Authors:  Paul J Currie; Christine D Coiro; Raya Duenas; Janet L Guss; Aaisha Mirza; Neta Tal
Journal:  Brain Res       Date:  2011-04-18       Impact factor: 3.252

Review 8.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

Review 9.  From Hans Selye's discovery of biological stress to the identification of corticotropin-releasing factor signaling pathways: implication in stress-related functional bowel diseases.

Authors:  Yvette Taché; Stefan Brunnhuber
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 10.  Role of corticotropin-releasing factor in alcohol and nicotine addiction.

Authors:  Sierra Simpson; Kokila Shankar; Adam Kimbrough; Olivier George
Journal:  Brain Res       Date:  2020-04-21       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.